<DOC>
	<DOCNO>NCT02098278</DOCNO>
	<brief_summary>The purpose study assess safety efficacy CAT-2003 patient chylomicronemia . The study evaluate effect CAT-2003 fast total chylomicron triglyceride level , well postprandial total chylomicron triglyceride clearance . This single-blind study . All patient receive placebo 1 week , CAT-2003 12 week 13 week treatment period .</brief_summary>
	<brief_title>Pilot Study To Assess CAT-2003 Patients With Chylomicronemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<criteria>Key Familial Chylomicronemia ( Fasting triglyceride ≥ 880 mg/dL Screening documented history plasma postheparin LDL activity &lt; 20 % normal genetic confirmation homozygosity compound heterozygosity lossoffunction mutation familial chylomicronemiacausing gene ) OR Nonfamilial Chylomicronemia ( Fasting triglyceride ≥ 440 mg/dL Screening documented history fast triglyceride ≥ 880 mg/dL ) Key History major cardiovascular event within 6 month Screening Type I diabetes mellitus use insulin History pancreatitis within 3 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>